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between the two antibodies, we inves-
tigated their activity against recombi-
nant proteins prior to staining of the
hair follicle originating from the head.
As controls, we observed both, the
positive staining signals with the first
antibody (Figures 2g and h) and the
negative staining signals without the first
antibody (Figures 2g and h). Preincuba-
tion of anti-TCHHL1 with recombinant
TCHHL1 completely abolished the
immunostaining pattern (Figure 2i); in
contrast, a parallel experiment in which
the monoclonal anti-trichohyalin anti-
body was preincubated with excessive
recombinant TCHHL1 did not alter the
immunoreactivity against trichohyalin
(Figure 2l). These data confirm no
cross-reactivity between the antibodies
that were used and indicate that tricho-
hyalin and TCHHL1 exhibit different
localization patterns in the skin. Given
the fact that the distal IRS is essential for
the exit of hair on the epidermal surface
(Tobin et al., 2002), TCHHL1 may have
a role, different from trichohyalin, in the
hair growth cycle.
In summary, our work has identified
and characterized a novel SFTP
member, TCHHL1, in the skin. We
show that TCHHL1 is an evolutionarily
conserved, lineage-specific gene that
originated before the emergence of
therian mammals. In contrast to tricho-
hyalin, TCHHL1 is localized in a
spatially restricted zone within the
distal IRS of the hair follicle. Thus,
TCHHL1 may be of fundamental
importance in hair morphogenesis.
Future studies will have to determine
the functional role of TCHHL1 in hair
biology.
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TO THE EDITOR
Nitric oxide (NO) is a key mediator in
cutaneous physiology (Weller, 2003),
but an increasing number of studies
suggest that both nitrate and nitrite, the
oxidative end products of NO metabo-
lism, exert biological activity as well.
These NO metabolites may have thera-
peutical potential for diseases such as
hypertension, myocardial infarction,
stroke, renal failure, ischemia/reperfu-
sion-related organ damage, and gastric
ulcers (Lundberg and Weitzberg, 2010).
Apart from the local topical adminis-
tration of NO and other NO-related
substances to improve wound healing
(Amadeu et al., 2008), dermal adminis-
tration can also be used as percutaneousAbbreviation: NO, nitric oxide
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systemic therapy for diseases correlated
with reduced NO availability.
The lower risk of N-nitrosamine
formation in comparison with oral
application supports a dermal adminis-
tration for enhancement of global NO
availability; however, possible toxicity
and inflammatory effects of NO on the
skin could hinder the use of NO-
releasing donors such as acidified
nitrite (Ormerod et al., 1999).
The dermal application of nitrite
without acidification could represent a
less harmful alternative to enhance
global NO availability, because nitrite
acts as a ‘‘NO prodrug’’ in vivo
(Suschek et al., 2006).
It has been shown that using a rodent
model and pharmacologically relevant
doses of dermal applied pH-neutral
nitrite solutions can result in a rapid
systemic distribution of nitrite and an
increase of NO-related metabolites in
blood and tissues (Garcia-Saura et al.,
2010). To translate these promising
findings to humans, we investigated
the percutaneous penetration and der-
mal nitrite uptake by human skin.
In brief, we used a modified Franz
diffusion cell (Franz, 1975) and accu-
rate split-thickness skin (0.3 or 0.7mm)
with intact epidermis obtained from
plastic surgery. Slightly acidified and
pH-neutral nitrite solutions (50mM
sodium nitrite in phosphate-buffered
saline; pH 7.4 or 50mM sodium nitrite,
100mM ascorbic acid in acetic/acetate
buffer; pH 5.5) were then deposited on
the donor chamber. Concentrations of
NO-related species (including nitrite)
in the receptor chamber (phosphate-
buffered saline, pH 7.4) were directly
measured by tri-iodide/ozone-based
chemiluminescence assay (Rassaf et al.,
2002). We observed that nitrite itself
under neutral conditions did not perme-
ate through intact epidermis, whereas
NO released by slightly acidified nitrite
did (see Figure 1). Therefore, it is
unlikely that an enhancement of global
NO availability after dermal nitrite ad-
ministration without acidification can be
achieved under intact skin conditions in
humans. Nevertheless, under certain skin
conditions, e.g., atopic dermatitis, when
skin barrier is not intact, the percuta-
neous penetration of nitrite is possible, as
a case study has reported (Saito et al.,
1996). On the other hand, the potent
inflammatory effect induced by acidified
nitrite used as a NO donor could be
attributable to the release of additional
mediators but not NO itself (Mowbray
et al., 2008). Thus, pure NO applied in
the form of NO donors such as NO
zeolite (Mowbray et al., 2008) or NO-
containing gas mixtures (Oplander et al.,
2010) may be excellent, safe, and
inexpensive alternative methods.
In conclusion, the dermal applica-
tion of nitrite and NO is a promising
approach to local and systemic therapy
for diseases correlated with reduced
NO availability. However, to determine
its full therapeutic potential, it is crucial
to identify an individualized as well as
optimized treatment regimen to mini-
mize negative side effects.
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Figure 1. Concentration of nitric oxide (NO)-related species in receptor chambers of Franz diffusion cell mounted with human split thickness skin during the
topical administration of acidified and pH-neutral solution of nitrite (50mM). The NO-related species measured by tri-iodide-based chemiluminescence assay
include NO, nitrite, and S- and N-nitroso compounds. Samples were obtained from Franz diffusion cell experiments. (a) The topical administration of 1ml
acidified nitrite (50mM sodium nitrite, 100mM sodium ascorbate, pH 5.5) on human split thickness skin with intact epidermis (0.3 and 0.7mm) for 1 hour led to
an increase of NO-related species in the receptor liquid (phosphate-buffered saline; pH 7.4). (b) No concentration changes of NO-related species were found
during the topical application of pH-neutral solution of nitrite (50mM in phosphate-buffered saline; pH 7.4) for 1 hour. Each data point represents three
independent experiments with skin samples obtained from three different healthy skin donors.
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TO THE EDITOR
Postmarketing studies could be ideal
post hoc sources of biologic materials.
The US Food and Drug Administration
(FDA) mandates postapproval/market-
ing studies that focus on the exploration
of safety signals associated with new
therapeutics. These studies are often
disease specific, large, and national in
scope, thereby improving the general-
izability of their findings. Several post-
marketing studies are currently being
conducted evaluating treatments for
psoriasis, atopic dermatitis (AD), and
acne. We demonstrate the feasibility of
obtaining DNA from a large national
community-based population of children
(PEER, http://www.thepeerprogram.com)
who have AD (Kapoor et al., 2008). In
addition, we assess the effectiveness of
using a prenotification letter and the use
of monetary incentives to improve parti-
cipation rates for obtaining buccal DNA
through the mail.
Children with AD are being recrui-
ted nationwide (by dermatologists,
pediatric dermatologists, pediatricians,
allergists, and/or other offices of treat-
ing physician) for the PEER study.
After enrollment, subjects are contacted
twice yearly, via mailed surveys, to
inquire about their general health and
the status of their AD. To obtain DNA
from these subjects, we assessed the use
of a prenotification letter. All eligible
subjects were contacted using a modi-
fication of the Dillman Tailored Design
Method (Dillman, 2000), with a pre-
notification letter describing our new,
not PEER participation related, request
for DNA. This process is detailed in the
Supplementary Figure S1 online with
Supplementary Text online.
All subjects (whether they returned a
prenotification postcard indicating in-
terest or not) were sent a study partici-
pation package. It included an Oragene
DNA Self-Collection Kit; an incentive
($1, $2, or $5 bill, which was randomly
allocated); return postage; and IRB
approved consent and assent forms that
described the study and use of DNA in
future studies.
Responses were evaluated with
respect to the full PEER population,
the subcohort that agreed to participate
via the prenotification letter (respon-
ders), those who did not respond to
our prenotification (non-responders),
and then those who ultimately provided
a sample (these individuals could have
been part of either of the two preceding
groups). Odds ratios with 95% con-
fidence intervals estimated from unad-
justed and adjusted logistic regression
models are presented (Table 1).
Overall, there were 3,264 eligible
participants of whom 46.4% were male
and 48.7% African-American; the average
age was 7.1(SD: 4.0) years and 732
(22.4%) provided sputum. Basic demo-
graphics and other variables of interest
differed little between the overall sample,
those who responded to our prenotification
letter agreeing to provide a saliva sample,
those who did not respond to our request,
and those who provided a sample (see
Supplementary Table S1).
Actual sample providers included
402 of the 674 participants from the
prenotification group (402/674 or
59.6%) and 330 participants who did
not respond to our prenotification mail-
ings (330/2590 or 12.7%; Table 1). The
odds ratio was 10.1 (8.4, 12.3), favoring
individuals who returned their prenoti-
fication postcard versus those who did
not. Adjusting for sex, age at enroll-
ment, African-American, asthma, sea-
sonal allergy, region of the country,
severity of dermatitis, and family in-
come had little effect (9.79 (8.04,
11.93)). Once a subject was mailed a
DNA self-collection kit (DNA Genotek,
Kanata, Ontario, Canada), the average
time to the submission of a sample did
not vary based on whether a subject had
agreed to submit a sample (61.5 days,
SD¼ 80.5) or not (64.3 days, SD¼78.8;
P¼ 0.64). After processing the saliva
specimens, on average, 30mg of DNA
(SD 28mg, median 20mg, 25% percentile
12mg, and 75% percentile 38mg) was
obtained. Age (Po0.01) but no other
factors influenced DNA quantity. By age
category, we obtained 20mg (SD 14mg) for
those 3 to o6 years of age, 30mg (26mg)
for those 46 but o9 years of age, and
31mg (31mg) for those 49 years of age.
The incentive also influenced the
response. As compared with the $1
incentive, the odds ratios were 1.01
(0.82, 1.24) for $2 and 1.26 (1.03, 1.51)
for $5 (test for trend; P¼ 0.016). The
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